Isoxazole derivatives, their preparation methods, and their uses as drugs
By developing isoxazole FXR agonists, the serious side effects of existing FXR agonists have been solved, and effective treatment of FXR-related diseases has been achieved, especially in non-alcoholic fatty liver, and has shown excellent improvement effects. Low dose requirements and good safety.
Patent Information
- Application Number
- CN202110694690.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-06-22
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2041-06-22
AI Technical Summary
Existing FXR agonists such as obeticcholic acid have severe side effects such as itching, hepatotoxicity and cardiovascular risk, which limits its application and lacks new structural types of non-cholic acid FXR agonists, making it difficult to effectively treat FXR-related diseases.
A completely new structure of isoxazole FXR agonist is developed, and compounds with FXR agonism activity and pharmaceutical compositions are prepared through specific compound general formulas and preparation methods for the treatment of FXR-related diseases.
The isoxazole FXR agonist showed significant FXR agonism activity, had excellent efficacy in the treatment of diseases such as non-alcoholic fatty liver, and had lower dose requirements and broader than the traditional drug obecholic acid The medicinal prospects are also less subacute toxicity, which is suitable for development as a drug.
Smart Images

Figure CN115504972B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of pharmaceutical chemistry, and in particular to a new isoxazole derivative, a preparation method thereof, and a pharmaceutical composition containing the derivative for use in preparing a drug for treating FXR-related diseases. The derivative structure involved in the present invention is unique and novel in this field. Background Art
[0002] Farnesoid X receptor (FXR, NR1H-4) is mainly expressed in the liver, esophagus, stomach, duodenum, small intestine, colon, etc. Bile acids such as chenodeoxycholic acid (CDCA) or its taurine or glycine amide conjugates are its endogenous ligands. Bile acids activate FXR after binding to it, and control the expression of multiple genes through a heterodimer complex with retinoid X receptor (RXR), including the expression of genes involved in the dynamic balance of bile acid, cholesterol, triglycerides, and lipoproteins in the liver and circulation. FXR activation can inhibit the synthesis of bile acid, and this effect can be achieved through two complementary mechanisms. In the liver, when the level of bile acid is too high, bile acid can bind to FXR as a physiological ligand and stimulate the expression of SHP, while SHP can form dimers with LRH-1 or LXPα to inactivate these two transcriptional regulatory factors, thereby inhibiting the gene transcription of CYP7α1 and reducing the expression of CYP7α1 protein. As the rate-limiting enzyme for cholesterol synthesis, the reduction of CYP7α1 expression can reduce the synthesis of myosin and thus reduce the synthesis of bile acid. In the small intestinal tissue, the activation of FXR can induce the transcriptional expression of the endocrine hormone FGF19. After secretion, FGF19 can enter the portal circulation and then bind to the FGFR4 receptor in the liver. The binding of FGF9 to FGFR4 can activate the MAPK signaling pathway in the liver, leading to the downregulation of CYP7α1 protein expression, thereby reducing the synthesis of bile acid through another pathway. In addition, after FXR binds to bile acid, it can also induce the transcriptional expression of BABP, enhance the reabsorption of bile, and enhance the enterohepatic circulation of bile acid. FXR can also regulate the expression of bile acid transporter MRP2 and bile salt export pump BSEP, promote bile output, and inhibit bile intake. Through this series of effects, the activation of FXR can regulate the synthesis, transport and metabolism of bile acid, reduce the accumulation of bile acid in the liver, reduce the burden on the liver and reduce the occurrence of fatty liver. In addition, after FXR activation, it can inhibit the expression of key genes involved in lipogenesis and triglyceride synthesis in the liver (such as SREBP-1c, etc.), regulate insulin sensitivity in peripheral tissues, and thus reduce triglyceride and blood sugar levels. In addition, FXR has been shown to regulate complex biological processes beyond metabolism, such as liver regeneration or the integrity of the intestinal barrier. FXR also controls the immune system of the intestine and liver and has a certain anti-inflammatory effect. Therefore, FXR agonists have potential therapeutic effects on non-alcoholic fatty liver disease, drug-induced liver injury, glycolipid metabolic syndrome, cholestatic liver disease, etc.
[0003] Obeticholic acid is a FXR receptor agonist with higher activity than the endogenous ligand CDCA. In a Phase IIa clinical study of non-alcoholic fatty liver disease (NAFLD), it showed significant improvement in insulin sensitivity and other beneficial effects on metabolism (Gastroenterology, 2013, 145, 574-582). A Phase IIb study of obeticholic acid showed that 72 weeks of treatment was also beneficial for the improvement of histopathology of non-alcoholic hepatitis (NASH). Phase III clinical studies have shown that obeticholic acid can improve liver fibrosis, histological features of fatty hepatitis, and biochemical indicators of the liver (Journal of Hepatology. 2019, 70). In the treatment of primary biliary cirrhosis (PBC), obeticholic acid was approved for marketing by the US FDA in May 2016 and by the EU in December 2016. However, as a bile acid FXR agonist, obeticholic acid has obvious safety defects. For example, clinical studies have found that obeticholic acid has severe side effects such as itching, hepatotoxicity, and cardiovascular risks, which greatly limits the application of obeticholic acid. Existing literature shows that non-bile acid FXR agonists may reduce toxic side effects. Therefore, the development of a new structural type of non-bile acid FXR agonists is a research hotspot in this field. Summary of the invention
[0004] In view of the above-mentioned problems existing in the prior art and unmet clinical needs, the purpose of the present invention is to provide a class of FXR agonists with a completely new structure and their applications, so as to provide a new class of potential drugs for preventing and / or treating FXR-related diseases.
[0005] The isoxazole FXR agonist of the present invention comprises an effective amount of a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof:
[0006]
[0007] in:
[0008] R1 and R2 are each independently selected from hydrogen, halogen, methyl, trifluoromethyl, trifluoromethoxy;
[0009] R3 is selected from cyclopropyl, isopropyl;
[0010] R4 is selected from any of the following structures:
[0011] More preferably, the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof is:
[0012] R1 and R2 are each independently selected from hydrogen, chlorine, trifluoromethyl, trifluoromethoxy;
[0013] R3 is selected from cyclopropyl, isopropyl;
[0014] R4 is selected from any of the following structures:
[0015] More preferred compounds of the present invention include, but are not limited to:
[0016]
[0017] Another aspect of the present invention relates to a pharmaceutical composition comprising a therapeutically effective dose of the compound or a pharmaceutically acceptable salt thereof and a suitable carrier, diluent or excipient.
[0018] The invention relates to use of the compound or its pharmaceutically acceptable salt or its pharmaceutical composition in preparing medicines for treating FXR-related diseases.
[0019] The present invention also relates to the use of the compound or its pharmaceutically acceptable salt or its pharmaceutical composition in the preparation of a drug for preventing and / or treating at least one of cholestatic liver disease, drug-induced liver injury, non-alcoholic fatty liver disease, alcoholic fatty liver disease, cholelithiasis, cholecystitis, inflammatory bowel disease, diabetes, obesity, hyperlipidemia and atherosclerosis.
[0020] Detailed description of the invention
[0021] Unless otherwise stated, the following terms used in the specification and claims have the following meanings.
[0022] Any general formula or structure shown herein, including compounds of general formula (I), is also intended to represent unlabeled and isotopically labeled forms of the compounds. Isotope-labeled compounds have the structure shown in the molecular formula given herein, except that one or more atoms are replaced by atoms with a selected atomic mass or mass number. Examples of isotopes that may be included in the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine and chlorine, and in the compounds of the present invention, any atom that is not explicitly indicated as a specific isotope is intended to represent any stable isotope of the atom. Unless otherwise stated, when a position is explicitly indicated with "H" or "hydrogen", it should be understood that the position is hydrogen of its isotopic composition. Therefore, in the compounds of the present invention, any atom explicitly indicated as deuterium (D) is intended to represent deuterium.
[0023] "Pharmaceutical composition" means a mixture containing one or more compounds of the present invention or their pharmaceutically acceptable salts, or prodrugs thereof, and other chemical components, such as pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to promote the absorption of the active ingredients by the organism and facilitate the active ingredients to exert their biological activity in the organism. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 : HE staining results of liver sections. DETAILED DESCRIPTION
[0025] The present invention will be further described below in conjunction with the examples. It should be noted that the following examples are only for illustration, and are not intended to limit the present invention. Various changes made by those skilled in the art based on the teachings of the present invention should be within the scope of protection of the claims of this application.
[0026] Example 1
[0027] 4-{1-[5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-methyl]piperidin-4-methoxy}benzoic acid (I-1)
[0028]
[0029] first step
[0030] 2,6-Dichlorobenzaldehyde oxime (2a)
[0031] At 0°C, a 3N sodium hydroxide solution (10.94 mL, 32.86 mmol) was added dropwise in batches to a suspension of hydroxylamine hydrochloride (1.31 g, 32.86 mmol) in water (1.7 mL). A solution of 2,6-dichlorobenzaldehyde (5.00 g, 28.57 mmol) in ethanol (1.7 mL) was added dropwise to the mixture. After mixing well, the mixture was heated at 90°C for 12 hours. Water (10 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (20 mL × 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the organic solvent was evaporated under reduced pressure to obtain 5.32 g of a white solid with a yield of 98%.
[0032] Step 2
[0033] 2,6-Dichlorobenzaldehyde chlorooxime (3a)
[0034] 2,6-Dichlorobenzaldehyde oxime 2a (5.32 g, 28.00 mmol) dissolved in DMF (5.5 mL) was slowly added dropwise to a solution of N-chlorosuccinimide (4.19 g, 31.36 mmol) in DMF (5.0 mL). After the addition, heat to 40°C for 1 hour. After the reaction, cool the reaction solution at room temperature, pour it into 10 times the amount of 0°C ice water, and extract with ethyl acetate (20 mL × 3). Combine the organic phases, dry them over anhydrous sodium sulfate, filter them, and evaporate the organic solvent under reduced pressure to obtain 4.45 g of a white solid with a yield of 71%.
[0035] Step 3
[0036] 5-Cyclopropyl-3-(2,6-dichlorophenyl)-isoxazole-4-carboxylic acid methyl ester (4a)
[0037] Triethylamine (5.5mL, 39.65mmol) was added dropwise to methyl 3-cyclopropyl-3-oxopropionate (2.82g, 19.82mmol), and the mixture was stirred at room temperature for 30 minutes. Subsequently, the mixture was cooled to 10°C, and 2,6-dichlorobenzaldehyde chlorooxime 3a (4.45g, 19.82mmol) dissolved in EtOH (5mL) was slowly added dropwise to the mixture. After the addition, the mixture was stirred at room temperature for 12 hours. The mixture was extracted with ethyl acetate (20mL×3), and the combined organic phases were washed with water (20mL×1) and saturated saline solution (20mL×2) in turn, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography (petroleum ether / ethyl acetate, 10:2, v / v) to give 3.46g of a white solid with a yield of 56%. 1 H NMR (300MHz, DMSO-d6) δ7.71-7.50 (m, 3H), 3.68 (s, 3H), 3.00-2.82 (m, 1H), 1.43-1.23 (m, 4H).
[0038] Step 4
[0039] 4-Bromomethyl-5-cyclopropyl-3-(2,6-dichlorophenyl)-isoxazole (5a)
[0040] A solution of 5-cyclopropyl-3-(2,6-dichlorophenyl)-isoxazole-4-carboxylic acid methyl ester 4a (3.46 g, 11.08 mmol) in THF (5 mL) was cooled to 0°C. While maintaining the temperature between -10°C and 0°C, LiAlH4 (0.84 g, 22.17 mmol) was added, and the resulting mixture was stirred for 30 minutes. Subsequently, water (1 mL) was slowly added at 0°C, 15% sodium hydroxide solution (1 mL) was added, and water (3 mL) was added, and the mixture was heated to room temperature and stirred for 15 minutes. Filtered through diatomaceous earth, the filter cake was washed with THF. The filtrate was extracted with ethyl acetate (20 mL×3), the organic phases were combined and dried over anhydrous sodium sulfate, and the organic solvent was evaporated under reduced pressure to obtain 2.97 g of a white solid with a yield of 90%. It was dissolved in CH2Cl2 (5mL), and the resulting mixture was cooled in an ice bath, and phosphorus tribromide (1mL, 9.96mmol) dissolved in CH2Cl2 (5.5mL) was slowly added dropwise to the above mixture, and the reaction was stirred at -5°C for 2 hours. The solvent was evaporated to obtain a yellow oily liquid, which was purified by column chromatography (petroleum ether / ethyl acetate, 10:1, v / v) to obtain 2.84g of a white solid with a yield of 90%. 1 H NMR (400MHz, DMSO-d6) δ7.74-7.58 (m, 3H), 4.46 (s, 2H), 2.48-2.42 (m, 1H), 1.24-1.13 (m, 4H).
[0041] Step 5
[0042] tert-Butyl 4-((4-(Methoxycarbonyl)phenoxy)methyl)piperidine-1-carboxylate (7a)
[0043] At room temperature, to acetonitrile (30mL) solution of methyl p-hydroxybenzoate 6a (5.10g, 33.52mmol), add 1-Boc-4-bromomethylpiperidine (13.99g, 50.28mmol), K2CO3 (13.90g, 100.56mmol) and catalytic amount of KI, the reaction mixture is heated to reflux after 24 hours, the reaction mixture is filtered and the organic solvent is evaporated to obtain a colorless oily product. Purification by column chromatography (petroleum ether / ethyl acetate, 10: 2, v / v) gives a white solid 7.24g, and the productive rate is 62%. 1 H NMR (400MHz, DMSO-d6) δ7.94-7.87 (m, 2H), 7.07-7.00 (m, 2H), 4.04-3.93 (m, 2H), 3.92 (d, J=6.4Hz, 2H) , 3.81(s, 3H), 2.81-2.65(m, 2H), 2.00-1.89(m, 1H), 1.81-1.70(m, 2H), 1.40(s, 9H), 1.24-1.10(m, 2H).
[0044] Step 6
[0045] Methyl 4-(piperidin-4-methoxy)benzoate (8a)
[0046] In an ice bath, trifluoroacetic acid / CH2Cl2 (1:1, 10 mL) was slowly added dropwise to a solution of tert-butyl 4-{[4-(methoxycarbonyl)phenoxy]methyl}piperidine-1-carboxylate 7a (7.24 g, 20.72 mmol) in CH2Cl2 (10 mL). After the addition, the reaction was stirred at room temperature for 90 minutes. Diluted with ethyl acetate, washed with 2N NaOH (20 mL×2) and saturated saline solution (20 mL×2) in sequence, dried over anhydrous sodium sulfate, filtered, and the organic solvent was evaporated under reduced pressure to obtain 4.79 g of a light yellow solid with a yield of 93%.
[0047] Step 7
[0048] Methyl 4-(1-(5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-methyl)piperidin-4-methoxy)benzoate (9a)
[0049] At room temperature, 4-bromomethyl-5-cyclopropyl-3-(2,6-dichlorophenyl)-isoxazole 5a (2.00 g, 5.76 mmol) was dissolved in acetonitrile and slowly added dropwise to an acetonitrile solution of methyl 4-(piperidinyl-4-methoxy)benzoate 8a (1.44 g, 5.76 mmol) and K2CO3 (2.39 g, 17.29 mmol). After the addition, the mixture was stirred at room temperature for 3 hours. Celite was filtered, the solvent was evaporated under reduced pressure, and the residue was purified by column chromatography (petroleum ether / ethyl acetate, 10:3, v / v) to obtain 2.33 g of a colorless oily liquid with a yield of 78%.
[0050] Step 8
[0051] 4-(1-(5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-methyl)piperidin-4-methoxy)benzoic acid (I-1)
[0052] Methyl 4-{1-[5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-methyl]piperidin-4-methoxy}benzoate 9a (2.33 g, 4.52 mmol) was dissolved in a mixed solvent of THF / CH3OH / H2O, and LiOH (0.23 g) was added. After the addition, the mixture was reacted at room temperature for 3 hours. The solvent was evaporated under reduced pressure, and 1N HCl was added for acidification. The solid was precipitated and filtered to obtain 1.82 g of a white solid with a yield of 80%. 1 HNMR (400MHz, DMSO-d6) δ7.87 (d, J=8.5Hz, 2H), 7.71-7.63 (m, 3H), 6.99 (d, J=8.5Hz, 2H), 3.87 (d, J= 6.1Hz, 2H), 3.39(s, 2H), 2.40-2.21(m, 1H), 1.96-1.73(m, 4H), 1.69-1.60(m, 1H), 1.32-1.00(m, 8H). 13 C NMR (101MHz, DMSO-d6) δ171.04, 167.37, 162.49, 159.87, 159.39, 135.09, 134.97, 132.63, 131.78 , 128.82, 128.05, 123.49, 115.07, 114.72, 71.80, 60.35, 52.18, 30.82, 28.33, 8.47, 7.75.ESI-MS m / z: 499.1[MH] - .
[0053] Example 2
[0054] 3-(1-(5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-methyl)piperidin-4-methoxy)benzoic acid (I-2)
[0055]
[0056] Referring to the preparation method of I-1, 1.39 g of white solid was obtained with a yield of 31%.
[0057] 1 H NMR (300MHz, DMSO-d6) δ7.65-7.45 (m, 5H), 7.30-7.20 (m, 1H), 6.94 (dd, J=8.0, 2.5Hz, 1H), 3.73 (d, J= 5.8Hz, 2H), 3.24(s, 2H), 2.40-2.26(m, 1H), 1.90-1.75(m, 2H), 1.71-1.56(m, 3H), 1.26-0.94(m, 8H). 13 C NMR (75MHz, DMSO-d6) δ171.15, 168.99, 159.93, 158.77, 137.40, 134.96, 132.43, 129.39, 128.67 ,128.43, 121.92, 117.81, 114.92, 111.91, 72.41, 52.93, 50.56, 35.53, 28.91, 8.29, 7.61.ESI-MS m / z: 499.1[MH] - .
[0058] Example 3
[0059] 3-(1-(5-cyclopropyl-3-(2-trifluoromethoxyphenyl)isoxazole-4-methyl)piperidin-4-methoxy)benzoic acid (I-3)
[0060]
[0061] Referring to the preparation method of I-1, 0.68 g of white solid was obtained with a yield of 29%.
[0062] 1 H NMR (400MHz, DMSO-d6) δ7.70-7.59 (m, 2H), 7.54-7.46 (m, 3H), 7.41-7.31 (m, 2H), 7.13-7.08 (m, 1H), 3.86 (d, J=5.1Hz, 2H), 3. 76(s, 2H), 2.71-2.63(m, 2H), 2.37-2.31(m, 1H), 1.88-1.77(m, 2H), 1.67-1.59(m, 3H), 1.12-1.07(m, 2H), 1.07-0.99(m, 4H). 13C NMR (101MHz, DMSO-d6) δ170.77, 167.36, 159.48, 158.64, 146.18, 132.84, 131.87, 131.49, 129.62, 127.44, 12 3.10, 121.51, 121.27, 120.88, 119.08, 118.71, 110.79, 72.08, 52.20, 49.78, 35.18, 28.43, 7.81, 7.23.ESI-MS m / z: 515.1[MH] - .
[0063] Example 4
[0064] 4-(1-(5-cyclopropyl-3-(2-trifluoromethylphenyl)isoxazole-4-methyl)piperidin-4-methoxy)benzoic acid (I-4)
[0065]
[0066] Referring to the preparation method of I-1, 0.56 g of white solid was obtained with a yield of 38%.
[0067] 1 H NMR (400MHz, DMSO-d6) δ7.95-7.90 (m, 2H), 7.88-7.85 (m, 2H), 7.82-7.77 (m, 2H), 6.98 (d, J=8.5Hz, 2H), 4.19 (s, 2H), 3.85 (d, J=4.8Hz, 2 H), 2.35-2.27(m, 1H), 2.19-2.11(m, 1H), 1.81-1.70(m, 4H), 1.37-1.27(m, 2H), 1.17-1.14(m, 2H), 1.14-1.12(m, 2H), 1.08-1.04(m, 2H). 13 C NMR (101MHz, DMSO-d6) δ170.47, 166.95, 162.11, 161.02, 132.33, 131.33, 130.48, 130.07, 128.30, 128 .00, 126.71, 126.45, 125.02, 122.99, 114.25, 71.63, 51.35, 47.39, 31.39, 29.43, 27.61, 7.87.ESI-MS m / z: 499.1[MH] - .
[0068] Example 5
[0069] 4-(1-(5-isopropyl-3-(2,6-dichlorophenyl)isoxazole-4-methyl)piperidin-4-methoxy)benzoic acid (I-5)
[0070]
[0071] Referring to the preparation method of I-1, 0.41 g of a white solid was obtained with a yield of 42%.
[0072] 1 H NMR (400MHz, DMSO-d6) δ7.85 (d, J=8.8Hz, 2H), 7.74-7.65 (m, 3H), 6.98 (d, J=8.8Hz, 2H), 4.02 (s, 2H), 3.85 (d, J=6.1Hz, 2H), 3.34-3.30(m, 2H), 2.74-2.67(m, 1H), 1.95-1.88(m, 1H), 1.85-1.75(m, 4H), 1.36-1.29(m, 8H). 13 C NMR (101MHz, DMSO-d6) δ174.48, 166.93, 162.00, 159.12, 134.53, 133.12, 131.35, 129.20, 128.39, 126.13, 123.09, 114.30, 71.29, 59.79, 50.05, 32.54, 25.94, 25.09, 20.77.ESI-MS m / z: 501.1[MH] - .
[0073] Example 6
[0074] 3-(1-(5-isopropyl-3-(2,6-dichlorophenyl)isoxazole-4-methyl)piperidin-4-methoxy)benzoic acid (I-6)
[0075]
[0076] Referring to the preparation method of I-1, 0.58 g of white solid was obtained with a yield of 30%.
[0077] 1H NMR (400MHz, DMSO-d6) δ7.73-7.69 (m, 2H), 7.68-7.63 (m, 1H), 7.51 (d, J=7.7Hz, 1H), 7.41-7.37 (m, 2H), 7.16 (dd, J=8.0, 2.1Hz, 1H) , 4.02 (s, 2H), 3.83 (d, J=5.7Hz, 2H), 3.33-3.29 (m, 2H), 2.75-2.67 (m, 1H), 1.93-1.87 (m, 1H), 1.85-1.76 (m, 4H), 1.37-1.28 (m, 8H). 13 C NMR (101MHz, DMSO-d6) δ175.30, 167.04, 159.12, 158.42, 134.53, 133.12, 132.23, 129.78, 129.21, 126.15, 121.69, 119.29, 114.66, 103.17, 71.22, 50.08, 46.74, 32.62, 25.93, 25.14, 20.78.ESI-MS m / z: 501.1[MH] - .
[0078] Example 7
[0079] 4-(1-(5-isopropyl-3-(2-trifluoromethylphenyl)isoxazole-4-methyl)piperidin-4-methoxy)benzoic acid (I-7)
[0080]
[0081] Referring to the preparation method of I-1, 0.87 g of white solid was obtained with a yield of 40%.
[0082] 1 H NMR (400MHz, DMSO-d6) δ7.98-7.91 (m, 1H), 7.89-7.84 (m, 3H), 7.84-7.75 (m, 2H), 6.99 (d, J=8.5Hz, 2H), 4.05 (s, 2H), 3.85 (d, J=5.7Hz, 2H) , 2.99-2.86 (m, 1H), 2.75-2.55 (m, 2H), 1.94-1.90 (m, 1H), 1.87-1.65 (m, 4H), 1.33 (d, J=6.8Hz, 6H), 1.27-1.22 (m, 1H), 1.20-1.16 (m, 1H). 13C NMR (101MHz, DMSO-d6) δ172.42, 167.37, 162.48, 161.49, 133.02, 131.78, 128.55, 127.47, 125.43, 123.50 , 121.42, 119.98, 114.72, 103.54, 71.79, 50.97, 47.08, 32.90, 26.24, 25.53, 23.20, 21.56, 21.19.ESI-MS m / z: 501.5[MH] - .
[0083] Example 8
[0084] 3-(1-(5-isopropyl-3-(2-trifluoromethylphenyl)isoxazole-4-methyl)piperidin-4-methoxy)benzoic acid (I-8)
[0085]
[0086] Referring to the preparation method of I-1, 0.75 g of a self-colored solid was obtained with a yield of 37%.
[0087] 1 H NMR (400MHz, DMSO-d6) δ7.92 (d, J=7.7Hz, 1H), 7.86-7.64 (m, 3H), 7.50 (d, J=7.6Hz, 1H), 7.41-7.34 (m, 2H), 7.18-7.10 (m, 1H), 4.02 (s, 2H), 3.80 (d, J =5.8Hz, 2H), 2.98-2.85(m, 1H), 2.67-2.49(m, 2H), 1.99-1.87(m, 1H), 1.87 -1.53(m, 4H), 1.31(d, J=6.8Hz, 6H), 1.26-1.20(m, 1H), 1.19-1.13(m, 1H). 13 C NMR (101MHz, DMSO-d6) δ167.50, 161.58, 158.95, 157.07, 133.05, 132.65, 130.95, 130.18, 128.49, 127.17, 125 .47, 122.74, 122.05, 120.02, 119.73, 115.01, 102.70, 71.99, 51.53, 48.34, 33.09, 26.25, 21.14, 14.53.ESI-MS m / z: 501.4[MH] - .
[0088] Example 9
[0089] 4-(1-(5-isopropyl-3-(2-trifluoromethoxyphenyl)isoxazole-4-methyl)piperidin-4-methoxy)benzoic acid (I-9)
[0090]
[0091] Referring to the preparation method of I-1, 0.86 g of white solid was obtained with a yield of 29%.
[0092] 1 H NMR (400MHz, DMSO-d6) δ7.85 (d, J=8.7Hz, 2H), 7.78-7.71 (m, 2H), 7.62-7.57 (m, 2H), 6.97 (d, J=8.7Hz, 2H), 4.10 (s, 2H) , 3.83(d, J=6.2Hz, 2H), 3.21-3.12(m, 2H), 2.63-2.57(m, 1H), 1.94-1.86(m, 1H), 1.80-1.66(m, 4H), 1.40-1.27(m, 8H). 13 C NMR (101MHz, DMSO-d6) δ173.38, 166.90, 161.96, 159.29, 145.72, 132.44, 132.13, 131.30, 128.25, 123 .05, 122.01, 121.66, 118.54, 114.25, 102.53, 71.21, 50.24, 46.71, 32.33, 25.76, 25.19, 20.74.ESI-MS m / z: 517.1[MH] - .
[0093] Example 10
[0094] 3-(1-(5-isopropyl-3-(2-trifluoromethoxyphenyl)isoxazole-4-methyl)piperidin-4-methoxy)benzoic acid (I-10)
[0095]
[0096] Referring to the preparation method of I-1, 0.74 g of white solid was obtained with a yield of 26%.
[0097] 1H NMR (400MHz, DMSO-d6) δ7.68-7.60 (m, 2H), 7.55-7.45 (m, 3H), 7.40 (s, 1H), 7.36-7.27 (m, 1H), 7.05 (d, J=7.5Hz, 1H), 3.74 (d, J=4.9Hz, 2H), 3.21 (s, 2H), 2.66-2.60 (m, 2H), 1.91-1.89 (m, 2H), 1.82-1.71 (m, 2H), 1.64-1.59 (m, 2H), 1.29 (d, J=6.9Hz, 6H), 1.06-0.99 (m, 2H). 13 C NMR (101MHz, DMSO-d6) δ172.21, 168.36, 159.24, 158.50, 146.21, 131.78, 131.42, 129.28, 127.40, 123.26, 121 .49, 121.23, 120.80, 118.67, 118.33, 114.55, 109.77, 72.00, 52.21, 49.88, 35.18, 28.47, 25.81, 20.53.ESI-MS m / z: 517.1[MH] - .
[0098] Embodiment 11
[0099] 4-(1-(5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-carboxyl)piperidin-4-methoxy)benzoic acid (I-11)
[0100]
[0101] 4-(Piperidin-4-methoxy)benzoic acid methyl ester 8a (1.00 g, 4.01 mmol) and CH2Cl2 (5 mL) were stirred and mixed evenly, and 5-cyclopropyl-3-(2,6-dichlorophenyl)-isoxazole-4-carbonyl chloride (1.40 g, 4.41 mmol) was added dropwise with a constant pressure dropping funnel while stirring. After the addition was completed, the mixture was reacted at room temperature for 3 hours. The mixture was extracted with a CH2Cl2 / water mixed solvent, the organic phases were combined and dried over anhydrous sodium sulfate, filtered, and the organic solvent was evaporated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate, 10:3, v / v) to obtain 1.80 g of a white solid with a yield of 85%. The mixture was dissolved in a mixed solvent of THF / CH3OH / H2O, and LiOH (0.18 g) was added. After the addition was completed, the mixture was reacted at room temperature for 3 hours, the solvent was evaporated under reduced pressure, 1N HCl was added for acidification, and a solid was precipitated. The mixture was filtered to obtain 1.59 g of a white solid with a yield of 91%.
[0102] 1H NMR (400MHz, DMSO-d6) δ7.89-7.84 (m, 2H), 7.65-7.58 (m, 2H), 7.58-7.50 (m, 1H), 7.01-6.94 (m, 2H), 3.86 (d, J=6.1Hz, 2H), 3.22-2.63(m, 4H), 2.28-2.21(m, 1H), 2.05-1.94(m, 1H), 1.84-1.64(m, 2H), 1.22-1.14(m, 4H), 1.09-0.99(m, 2H). 13 C NMR (101MHz, DMSO-d6) δ172.23, 167.56, 162.51, 160.44, 158.19, 134.96, 132.93, 131.77 ,128.99,127.18,123.80,114.64,112.55,72.07,51.20,35.51,28.68,9.39,8.75.ESI-MS m / z: 513.1[MH] - .
[0103] Example 12
[0104] 2-(6-((1-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methyl)piperidin-4-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid (I-12)
[0105]
[0106] first step
[0107] Methyl 2-(6-hydroxybenzofuran-3-yl)acetate (4b)
[0108] Ethyl 4-chloroacetoacetate (4.25 ml, 31.43 mmol) was dissolved in 20 ml concentrated sulfuric acid at 0°C. The formed light yellow viscous solution was placed in an ice bath and cooled to about -5°C. Resorcinol (3.15 g, 28.57 mmol) was added in batches, and the internal temperature was controlled below 0°C. After the addition was completed, the mixture was stirred at room temperature for 2 h. The reaction solution was poured into 50 ml of ice water, and a white solid precipitated. The solution was filtered off with suction, and the filter cake was washed with water (5 ml × 2). It was dried to obtain 5.6 g of an off-white solid with a crude yield of 82.3%. The above crude product (2 g, 9.50 mmol) was placed in a 200 ml single-necked bottle, and 1N NaOH solution (100 ml) was added. The solution immediately turned into a thick yellow color. The above solution was placed in an oil bath and heated under reflux for 2 h. After the reaction was completed, it was cooled to room temperature and the pH was adjusted to 2-3 with concentrated sulfuric acid. The resulting solution was extracted with ethyl acetate (30 ml × 4), and the organic phases were combined, washed with saturated brine (20 ml × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated under reduced pressure to remove the solvent to obtain 1.3 g of gray-brown columnar crystals. The crude yield was 71.2%. The above crude product (1 g, 5.20 mmol) was suspended in 10 ml of methanol, and 0.5 ml of concentrated sulfuric acid was added dropwise. After the addition was completed, the temperature was raised to reflux for reaction for about 4 h. After the reaction was completed, the methanol was evaporated under reduced pressure, and the residual liquid was poured into 30 ml of water, extracted with ethyl acetate (20 ml × 3), and the organic phases were combined, washed with saturated sodium bicarbonate solution (15 ml × 2), washed with saturated brine (15 ml × 2), respectively, dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated under reduced pressure to remove the solvent to obtain a yellow-brown oil, which was purified by column chromatography (petroleum ether / ethyl acetate, 80:20, v / v) to obtain 0.75 g of a light yellow solid with a yield of 70%.
[0109] 1 H NMR (300MHz, DMSO-d6) δ: 9.54 (s, 1H), 7.69 (s, 1H), 7.33 (d, J=8.41Hz, 1H), 6.87 ( d, J=1.89Hz, 1H), 6.75, 6.72 (dd, J=2.01, 8.40Hz, 1H), 3.71 (s, 2H), 3.63 (s, 3H).
[0110] Step 2
[0111] Methyl 2-(6-hydroxy-2,3-dihydro-1-benzofuran-3-yl)acetate (5b)
[0112] Methyl 2-(6-hydroxybenzofuran-3-yl)acetate 4b (2.25 g, 10.91 mmol) was dissolved in methanol, and a catalytic amount of palladium on carbon (0.22 g) was added. The mixture was replaced with hydrogen three times, and hydrogen was introduced and stirred at room temperature for 24 hours. After the reaction was completed, the mixture was filtered through celite, the filter cake was washed, and the filtrate was evaporated under reduced pressure to remove the solvent to obtain 2.09 g of an off-white solid with a yield of 92%.
[0113] 1 H NMR (300MHz, CDCl3) δ: 6.97 (d, J=8.71Hz, 1H), 6.31-6.34 (m, 2H), 4.82 (brs, 1H), 4.75 (t, J=9.10Hz, 1H), 4.26, 4.24 (dd, J=5. 72, 9.10Hz, 1H), 3.74-3.84 (m, 1H), 3.72 (s, 3H), 2.74, 2.69 (dd, J=5.72, 16.41Hz, 1H), 2.55, 2.50 (dd, J=9.11, 16.41Hz, 1H).
[0114] Step 3
[0115] tert-Butyl 4-(((3-(2-methoxy-2-oxoethyl)-2,3-dihydrobenzofuran-6-yl)oxy)methyl)piperidine-1-carboxylate (6b)
[0116] At room temperature, to 2-(6-hydroxy-2,3-dihydro-1-benzofuran-3-yl) methyl acetate 5b (2.09g, 10.04mmol) in acetonitrile (30mL), add 1-Boc-4-bromomethylpiperidine (2.79g, 10.04mmol), K2CO3 (4.16g, 30.11mmol) and catalytic amount of KI, the reaction mixture is heated to reflux for 24 hours, the reaction mixture is filtered and the organic solvent is evaporated to obtain a colorless oily product. Purification by column chromatography (petroleum ether / ethyl acetate, 10: 3, v / v) gives a white solid 2.53g, and the yield is 62%.
[0117] Step 4
[0118] Methyl 2-(6-(piperidin-4-ylmethoxy)-2,3-dihydrobenzofuran-3-yl)acetate (7b)
[0119] Under ice bath conditions, trifluoroacetic acid / CH2Cl2 (10 mL) was slowly added dropwise to a solution of tert-butyl 4-(((3-(2-methoxy-2-oxoethyl)-2,3-dihydrobenzofuran-6-yl)oxy)methyl)piperidine-1-carboxylate 6b (2.53 g, 6.24 mmol) in CH2Cl2 (10 mL). After the addition, the reaction was stirred at room temperature for 90 minutes. Diluted with ethyl acetate, washed with 2N NaOH (20 mL×2), saturated saline solution (20 mL×2), dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure to obtain 1.21 g of a light yellow solid with a yield of 64%.
[0120] Step 5
[0121] Methyl 2-(6-((1-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methyl)piperidin-4-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetate (8b)
[0122] At room temperature, 4-bromomethyl-5-cyclopropyl-3-(2,6-dichlorophenyl)-isoxazole (1.64 g, 4.71 mmol) was dissolved in acetonitrile and slowly added dropwise to an acetonitrile solution of 2-(6-(piperidin-4-ylmethoxy)-2,3-dihydrobenzofuran-3-yl)acetate 7b (1.21 g, 3.96 mmol) and K2CO3 (1.64 g, 11.89 mmol). After the addition, the mixture was stirred at room temperature for 3 hours. Celite was filtered, the solvent was evaporated under reduced pressure, and the residue was purified by column chromatography (petroleum ether / ethyl acetate, 10:3, v / v) to obtain 1.48 g of a colorless oily liquid with a yield of 65%.
[0123] Step 6
[0124] 2-(6-((1-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methyl)piperidin-4-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid (I-12)
[0125] Methyl 2-(6-((1-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methyl)piperidin-4-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetate 8b (1.48 g, 2.59 mmol) was dissolved in a mixed solvent of THF / CH3OH / H2O, and LiOH (0.15 g) was added. After the addition, the mixture was reacted at room temperature for 3 hours. The solvent was evaporated under reduced pressure, and 1N HCl was added for acidification. A solid was precipitated and filtered to obtain 1.03 g of a white solid with a yield of 71%.
[0126] 1 H NMR (300MHz, DMSO-d6) δ7.73-7.51(m, 3H), 7.11-7.01(m, 1H), 6.39-6.31(m, 2H), 4.28-4.05(m, 2H), 3.72-3.65(m, 3H), 3.61(s, 2H), 2. 80-2.55 (m, 4H), 1.72-1.62 (m, 2H), 1.34 (dd, J=17.6, 11.8Hz, 2H), 1.22 (d, J=9.6Hz, 2H), 1.18-1.08 (m, 4H), 0.97-0.78 (m, 2H).ESI-MS m / z: 555.1[MH] - .
[0127] Embodiment 13
[0128] 2-(6-((1-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methyl)piperidin-4-yl)methoxy)benzofuran-3-yl)acetic acid (I-13)
[0129]
[0130] Referring to the preparation method of Example 12, 1.19 g of white solid was obtained with a yield of 31%.
[0131] 1 H NMR (500MHz, DMSO-d6) δ7.72 (s, 1H), 7.60 (d, J=7.6Hz, 2H), 7.56-7.51 (m, 1H), 7.42 (d, J= 8.5Hz, 1H), 7.09 (d, J=1.7Hz, 1H), 6.84-6.80 (m, 1H), 3.74 (d, J=5.7Hz, 2H), 3.58 (s, 2H), 3.21(s, 2H), 2.66(d, J=10.6Hz, 2H), 2.34-2.28(m, 1H), 1.90-1.89(m, 1H), 1.83-1.79(m, 2H), 1.62 (d, J=9.7Hz, 2H), 1.12-1.08-1.04 (m, 2H), 1.07-1.04 (m, 2H), 1.03-0.98 (m, 2H). 13 C NMR (126MHz, DMSO-d6) δ172.26, 170.74, 159.51, 157.04, 155.53, 142.21, 134.58, 132.04, 128.28, 128.03, 1 21.12, 120.35, 114.27, 111.89, 111.46, 96.65, 72.57, 52.55, 50.18, 29.66, 28.57, 21.32, 7.87, 7.23.ESI-MS m / z: 553.1[MH] - .
[0132] Embodiment 14
[0133] 6-((1-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methyl)piperidin-4-yl)methoxy)-2-naphthoic acid (I-14)
[0134]
[0135] Referring to the preparation method of I-1, 0.69 g of white solid was obtained with a yield of 43%.
[0136] 1H NMR (300MHz, DMSO-d6) δ8.51-8.50 (m, 1H), 8.00 (d, J=9.1Hz, 2H), 7.92-7. 89(m, 2H), 7.40-7.37(m, 2H), 7.22-7.18(m, 2H), 4.20(s, 2H), 3.95-3.88( m, 2H), 2.36-2.32 (m, 1H), 2.24-2.11 (m, 2H), 1.99-1.95 (m, 1H), 1.86-1.7 8(m, 4H), 1.35-1.32(m, 2H), 1.17-1.16(m, 2H), 0.87-0.81(m, 2H).ESI-MS m / z:549.1[MH] - .
[0137] Embodiment 15
[0138] Tablets containing active agent I-1:
[0139]
[0140]
[0141] The active ingredient, pregelatinized starch and microcrystalline cellulose are sieved and fully mixed, polyvinyl pyrrolidone solution is added, mixed, a soft material is prepared, sieved, wet granules are prepared, and dried at 50-60°C. Sodium carboxymethyl starch, magnesium stearate and talc are sieved and added to the above granules for tableting.
[0142] Example 16 Determination of the agonist activity of the compounds of the present invention on FXR
[0143] Different concentrations of test compounds were mixed with FXR-LBD, fluorescein-SRC2-2 and Tb anti-GST antibodies and added to a 384-well plate, and CDCA was used as a positive control. The 384-well plate was mixed on a plate shaker and incubated in the dark for 3 hours at room temperature. EnVision multi-label reader (PerkinElmer) was used to detect TR-FRET signals of different wavelengths. The TR-FRET ratio was calculated by dividing the emission signal at 520nm by the emission signal at 495nm. Excitation efficiency % = (compound signal-blank signal) / (control signal-blank signal)×100, with CDCA as the control signal and DMSO as the blank signal. EC 50 The values were obtained using GraphPad 5.00. Example Compound FXR Agonist Activity EC 50 See Table 1 for values.
[0144] Table 1: FXR agonist activity
[0145]
[0146] Conclusion: The compounds of the present invention have obvious agonist activity on FXR, among which I-1, I-5 and I-9 have relatively excellent agonist activity.
[0147] Example 17 The improving effect of the compound of the present invention on non-alcoholic fatty liver disease
[0148] Eight-week-old C57BL / 6 mice were randomly divided into a normal group, a model group, a positive control group, and a test compound treatment group, with 7 mice in each group. The mice in the model group and the drug group were given a Western diet (containing 21.1% fat, 41% fructose, and 1.25% cholesterol), supplemented with drinking water containing 23.1g / L fructose and 18.9g / L glucose, and intraperitoneally injected with CCl4 olive oil solution twice a week, and the injection volume of carbon tetrachloride was 0.2μL / g, and the NASH model was induced for 12 consecutive weeks. Starting from the 8th week of model induction, the mice in the normal group and the model group were gavaged with 0.5% sodium carboxymethyl cellulose solution, and the mice in the drug group were gavaged with obeticholic acid (20mg / kg) or I-9 (10mg / kg), once a day for 4 consecutive weeks. After the last administration, the mice were fasted for 8h and blood was collected by orbital bleeding under anesthesia. The mice were then killed to remove the liver, and the liver tissue of the left lobe of appropriate size was uniformly cut and fixed in tissue fixative after washing with physiological saline. The remaining tissues were placed in cryopreservation tubes and sealed with liquid nitrogen and then stored in a -80°C refrigerator for later use. Liver tissue was taken for HE staining to observe the improvement of fatty liver. The staining results are shown in the attached Figure 1 .
[0149] The experimental results show that after long-term administration to mice with non-alcoholic fatty liver model, I-9 (10 mg / kg) achieved more significant improvements in the degree of hepatic fatty degeneration, inflammatory infiltration and balloon-like lesions compared with obeticholic acid (20 mg / kg), indicating that the effect of the compound I-9 of the present invention in improving non-alcoholic fatty liver is significantly better than obeticholic acid, and the dosage used is lower, and it has broader prospects for pharmaceutical development.
[0150] Example 18 Subacute toxicity study of the compounds of the present invention
[0151] Eight-week-old ICR mice were randomly divided into groups, with 12 mice in each group, half male and half female. They were set as blank group, I-5 (250mg / kg), I-5 (500mg / kg), I-9 (250mg / kg), I-9 (500mg / kg). The drug was administered continuously for 30 days. The weight of the animals was measured once a week at the beginning of the experiment and after the experiment, and the daily feed intake and drinking water intake were recorded. The general performance, behavior, poisoning symptoms and death of the animals were observed and recorded every day (the coat, skin, eyes, mucous membranes, and secretions, breathing, circulation, autonomic nervous system, body and limb activities of the experimental animals, mental behavior, tail color, and the color of feces and urine and other physical and chemical properties). The mice were opened and examined one by one to determine whether the mice had symptoms of poisoning, and the time and order of symptoms were recorded. If mice were found to be dead or in a dying state, they should be treated in time, and the symptoms and death time of the mice should be recorded in detail, and the main organs should be fixed for histopathological examination. At the end of the experiment, the mice were fasted for 12 hours and blood was collected. The mice were killed by cervical dislocation, and the organs of each mouse were observed. The liver, kidney, spleen, testis, heart, lung, brain and other organs were weighed, and the organ-to-body ratio was calculated. At the same time, blood count and blood biochemistry tests were performed, and the liver, kidney, spleen, stomach, intestine, testis and ovary were kept for pathological histological observation. The blood count was measured by a fully automatic blood analyzer. For blood biochemistry tests, serum was measured by a fully automatic biochemical analyzer. The organs were paraffin-sectioned and stained with HE.
[0152] The experimental results show that: no animal died during the entire experimental process, and there were no significant differences in body weight, diet and drinking water, general performance and behavior, blood count and blood biochemical results between the group treated with the compounds of the present invention and the normal group; the results of gross anatomical observation and histological examination showed that no obvious lesions were found in the organs of each dosage group; the above results show that the subacute toxicity of the compounds I-5 and I-9 of the present invention is relatively low, and they are suitable for development as drugs.
Claims
1. A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof: in: R1 and R2 are each independently selected from hydrogen, chlorine, trifluoromethyl, trifluoromethoxy; R3 is selected from cyclopropyl, isopropyl; R4 is selected from any of the following structures:
2. A compound of the general formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from: .
3. A pharmaceutical composition comprising the compound according to any one of claims 1 to 2 or a pharmaceutically acceptable salt thereof and a suitable carrier or excipient.
4. Use of a compound as defined in any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof in the preparation of a medicament for preventing and / or treating non-alcoholic fatty liver disease.
Citation Information
Patent Citations
Bridged bicyclic compounds as farnesoid x receptor modulators
CN111295382A
Compounds useful in modulating the farnesoid x receptor and methods of making and using the same
CN112638473A
Substituted azole aromatic heterocycles as inhibitors of 11beta-HSD-1
US20080021022A1
Compounds for modulating fxr
WO2020249064A1
